Literature DB >> 34341851

Oral manifestations of graft-versus-host disease in patients submitted to allogeneic hematopoietic stem cell transplantation: the experience of a Brazilian Cancer Center.

Ana Cláudia Scaraficci1, Patrícia Maria Fernandes1,2, Fabio Abreu Alves1, Jayr Schmidt Filho3, Graziella Chagas Jaguar4.   

Abstract

PURPOSE: Graft-versus-host disease (GVHD) is an important complication of allogeneic hematopoietic stem cell transplantation (AHCT) that affects several organs, including the mouth.
OBJECTIVES: The aim of the present study was to describe the prevalence and clinical manifestations of oral GVHD, to determine the time interval from AHCT to the onset of oral GVHD manifestations, to identify predictive factors of oral GVHD, and to evaluate the survival rates of patients diagnosed with oral GVHD.
METHODS: Medical records of 147 patients who underwent AHCT between January 2010 and January 2015 were reviewed for clinical features and the statistical establishment of risk factors.
RESULTS: Of the 147 patients in the study, 99 (67.3%) developed GVHD. The skin was the most affected site (45.6%), followed by the gastrointestinal tract (27.9%) and oral cavity (17.7%). The mean post-AHCT oral GVHD development time was 229 days. Among patients with oral GVHD, pain was the main complaint (96.2%) followed by xerostomia (65.4%). The most common oral manifestations were ulcers (53.8%) followed by striae-associated ulcers (19.2%), mostly affecting the buccal mucosa and tongue. Seventy-three patients (48.6%) died within 20 months of receiving AHCT. Cox regression analysis indicated that patients who received myeloablative conditioning regimen had higher survival rate than those who underwent a reduced-intensity conditioning regimen (RR = 0.541; 95% CI, 0.334-0.878; p = 0.03).
CONCLUSION: The mouth was the third most common GVHD-affected site. Pain, xerostomia, and ulcers with or without striae were the main clinical manifestations of GVHD observed in our study cohort. Reduced-intensity conditioning regimen showed significant relationship with mortality risk.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Graft-versus-host disease; Hematopoietic stem cell transplantation; Oral manifestation

Mesh:

Year:  2021        PMID: 34341851     DOI: 10.1007/s00520-021-06349-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  3 in total

Review 1.  Oral malignancies following HSCT: graft versus host disease and other risk factors.

Authors:  Federica Demarosi; Giovanni Lodi; Antonio Carrassi; Davide Soligo; Andrea Sardella
Journal:  Oral Oncol       Date:  2005-04-14       Impact factor: 5.337

2.  Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease.

Authors:  E Bardellini; F Amadori; G Conti; F Veneri; A Majorana
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2019-03-01

Review 3.  Oral carcinoma after hematopoietic stem cell transplantation--a new classification based on a literature review over 30 years.

Authors:  Astrid L D Kruse; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2009-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.